Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) and Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Profitability
This table compares Celldex Therapeutics and Autolus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Celldex Therapeutics | N/A | -52.66% | -47.58% |
| Autolus Therapeutics | -186.37% | -263.25% | -48.04% |
Insider & Institutional Ownership
72.8% of Autolus Therapeutics shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Valuation & Earnings
This table compares Celldex Therapeutics and Autolus Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celldex Therapeutics | $1.54 million | 1,430.40 | -$258.76 million | ($4.30) | -6.52 |
| Autolus Therapeutics | $75.39 million | 3.85 | -$287.53 million | ($0.97) | -1.12 |
Celldex Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Celldex Therapeutics and Autolus Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celldex Therapeutics | 1 | 1 | 11 | 0 | 2.77 |
| Autolus Therapeutics | 1 | 1 | 4 | 2 | 2.88 |
Celldex Therapeutics presently has a consensus target price of $64.08, indicating a potential upside of 128.54%. Autolus Therapeutics has a consensus target price of $10.00, indicating a potential upside of 817.43%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Celldex Therapeutics.
Summary
Autolus Therapeutics beats Celldex Therapeutics on 9 of the 15 factors compared between the two stocks.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.
About Autolus Therapeutics
Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient’s T cells to recognize and attack specific cancer cells, using the company’s proprietary cell-engineering technology. The company’s lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
